Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs SMX Security Matters plc (SMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs SMX Security Matters plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while SMX Security Matters plc trades at $15.61 (market cap $15.03M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2654× SMX Security Matters plc's market cap, and Alnylam Pharmaceuticals, Inc. is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| ALNY | SMX | |
|---|---|---|
Market Cap | $39.89B | $15.03M |
Sector | Health | Technology |
52-Week High | $491.22 | $313.26K |
52-Week Low | $278.09 | $12.87 |
Enterprise Value | $38.15B | $12.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SMX trades at $15.65, down 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows negative profitability with a ROE of -2,216.26% and ROA of -398.22%, while the P/B ratio stands at 1.7. Recent corporate actions include two reverse stock splits in May and June 2026. News highlights the company's focus on recycled plastic traceability amid new state recycling mandates, positioning it in a growing regulatory environment.
The outlook for SMX is challenged by weak profitability but supported by potential demand from recycling regulations. Investment opportunity lies in policy-driven adoption of its traceability technology, while risks include execution hurdles and sustained negative returns. The stock's near-term direction may hinge on converting regulatory tailwinds into tangible financial improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
